Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corp. and heliosDx have entered into a Scientific Collaboration Agreement aimed at developing new diagnostic technologies for effective disease management. This partnership, driven by Halberd's Chief Medical Officer, Dr. Patricio F. Reyes, focuses on improving diagnostic methods for neurological disorders and COVID-19. The collaboration is expected to enhance sample collection and processing, providing significant clinical outcomes and the potential for insurance reimbursement through CPT codes. Both companies are optimistic about the project's success and its impact on patient care.
Halberd Corporation (OTC PINK:HALB) has announced a breakthrough in laboratory testing, successfully eradicating the primary building block of neurofibrillary tangles associated with Alzheimer's Disease. Utilizing a patented extracorporeal process combined with a patent-pending laser technique, tests performed at Youngstown State University achieved near-total elimination of the Phosphorylated Tau antigen. This achievement paves the way for further studies and potential collaborations, particularly with military and sports organizations, to combat neurodegenerative diseases.
Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli as Vice-President of Mergers & Acquisitions. Mirabelli brings over 30 years of experience in the bio-pharmaceutical sector, focusing on product development, P&L management, and regulatory affairs. His expertise is expected to aid Halberd's R&D efforts in developing treatments for PTSD and Alzheimer's Disease. Halberd holds exclusive rights to multiple medical patents, including treatments for COVID-19. The company is in compliance with OTC Market reporting requirements.
Halberd Corp (OTC PINK:HALB) announced significant progress in its Alzheimer's Disease research conducted at Youngstown State University and Arizona State University. The company reported promising results from experiments on Phosphorylated Tau, a key protein linked to Alzheimer's. Following these findings, Halberd plans to conduct further replication tests and publish scientific findings. The company also noted successful results from tests on E. Coli. Halberd holds exclusive rights to several patents for extracorporeal treatments targeting various diseases, including COVID-19.
Halberd Corporation (OTC PINK:HALB) announced a Notice of Allowance for a patent from the US Patent Office for treating Cockayne Syndrome, a rare neurodegenerative disorder. This patent could pioneer methods to slow aging and strengthen Halberd's intellectual property in developing treatments for various diseases, including PTSD and Alzheimer's. The granted patent may allow control over Death-Associated Protein 1 (DAP1) levels, potentially reducing premature deaths. The CEO emphasized the company's strategy to target major diseases lacking effective cures.
Halberd Corp. (OTC PINK:HALB) has filed a U.S. joint provisional patent application for a novel treatment for Alzheimer's Disease using extracorporeal radio frequency. Developed through research at Arizona State University and Youngstown State University, the technology uses radio frequency waves to target and eliminate Alzheimer's-related antigens from bodily fluids.
Dr. Mitchell S. Felder, CTO, highlighted the promising results of their testing, while William A. Hartman, CEO, emphasized the reduced side effects associated with this treatment approach.
Halberd Corporation (OTC PINK:HALB) announces the launch of its nutraceutical product, Vita-Shield-MaxTM, designed to support a healthy immune system. This product is now available on www.vitashieldmax.com. The formulation is based on extensive research and is positioned as an alternative for immunity support amid rising COVID-19 cases. Halberd is also committed to expanding its nutraceutical division and collaborating with universities on treatments for COVID-19 and other diseases.
Halberd Corporation (OTC PINK: HALB) has gained media attention from WKBN, a local CBS affiliate, for its revolutionary research at Youngstown State University (YSU) on disease treatment technologies. The company focuses on eliminating disease antigens related to conditions like Alzheimer's Disease and PTSD via a unique methodology that avoids bodily exposure. The research, led by Dr. William Sturrus at YSU, aims to establish proof of concept for Halberd's patent-protected technology, which could change global medical practices.
Halberd's CTO emphasized the method's rapid efficacy and safety compared to traditional treatments.
Halberd Corporation (OTC PINK:HALB) has appointed Dr. Ned Kronfol to its Scientific Advisory Board, enhancing its focus on extracorporeal treatment for blood-borne diseases. Dr. Kronfol's expertise will expedite advancements in tackling conditions like septicemia and cancer. The company emphasizes its strategic positioning in a high-demand healthcare area, where it has strong patent protection. Ongoing experiments at various universities are aimed at proof-of-concept for their patented methods. The corporation also plans to initiate FDA applications following initial successes in research.
Halberd Corporation (OTC PINK:HALB) has announced the shipment of its Vita-Shield-MaxTM nutraceutical product, coinciding with a rise in Covid-19 cases due to the Delta Variant. CEO William A. Hartman indicated that sales will commence shortly, with purchasing details to follow. The company previously released a 120-page compilation of medical articles supporting Vita-Shield-Max. Halberd holds exclusive rights to several patents for treatments related to COVID-19, acknowledging ongoing risks and uncertainties linked to the pandemic and its effect on operations.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
